Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study

Cardiovascular Diabetology

Guang Ning¹  Linhong Wang²  Shenghan Lai³  Mei Zhang²  Yichong Li²  Limin Wang²  Yong Jiang²  Wenhua Zhao²  Jichao Sun¹  Baihui Xu¹  Lin Ding¹  Di Zhang¹  Meng Dai¹  Jieli Lu¹  Yufang Bi¹  Weiqing Wang¹  Min Xu¹  Yu Xu¹  Tiange Wang¹ 

[1] State Key Laboratory of Medical Genomics, Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health, National Clinical Research Center for Metabolic Diseases, and Shanghai Clinical Center for Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai 200025, China;National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China;Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

关键词: China;    Control;    Dyslipidemia;    Hypertension;    Diabetes;   

Others  :  1136321
DOI  :  10.1186/s12933-015-0191-6

 received in 2014-11-26, accepted in 2015-02-10,  发布年份 2015

【 摘 要 】

Background

The diagnosis of diabetes has important clinic implications for the prevention and management of cardiometabolic disorders. We aimed to investigate the awareness, treatment and control of hypertension and dyslipidemia in previously-diagnosed and newly-diagnosed diabetes in Chinese adult population.

Methods

We conducted a cross-sectional survey in a nationally representative sample of 98658 Chinese adults aged 18 years or older in 2010, using a complex, multistage, probability sampling design. Glycemic status were defined according to the 2010 American Diabetes Association criteria. Hypertension was diagnosed by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Dyslipidemia was diagnosed by the 2004 National Cholesterol Education Program Adult Treatment Panel III.

Results

The weighted prevalence of hypertension and dyslipidemia gradually increased in adults with normal glucose regulation, prediabetes, newly-diagnosed diabetes and previously-diagnosed diabetes. Compared to newly-diagnosed diabetes patients, previously-diagnosed diabetes patients were more likely to be aware of hypertension (weighted percentage [95% confidence interval]: 55.2% [52.9%-57.5%] vs 37.6% [35.9%-39.3%]) and dyslipidemia (33.9% [31.8%-36.1%] vs 12.8% [11.7%-13.9%]), to receive blood pressure-lowing (43.7% [41.5%-46.0%] vs 27.5% [26.0%-29.0%]) and lipid-lowering (18.9% [17.2%-20.7%] vs 5.4% [4.6%-6.2%]) therapies, and to have controlled blood pressure (4.7% [3.5%-6.2%] vs 3.5% [2.6%-4.8%]) and lipid (15.9% [12.3%-20.3%] vs 9.5% [6.4%-13.8%]) levels.

Conclusions

Detection and control of hypertension and dyslipidemia is far from optimal in Chinese adults, especially in newly-diagnosed diabetes. Improved screening for diabetes is required to promote a better prevention, treatment and control of hypertension and dyslipidemia in China.

【 授权许可】

   
2015 Wang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al.: Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5):e69-171.
• [2]Lawes CM, Vander Hoorn S, Rodgers A: Global burden of blood-pressure-related disease, 2001. Lancet 2008, 371(9623):1513-8.
• [3]Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al.: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370(9602):1829-39.
• [4]Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, et al.: Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003, 32(4):563-72.
• [5]Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al.: Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama 2009, 302(4):412-23.
• [6]Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al.: National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377((9765):578-86.
• [7]Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al.: Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama 2013, 310(9):959-68.
• [8]Tolonen H, Keil U, Ferrario M, Evans A: Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol 2005, 34(1):181-92.
• [9]Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al.: Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006, 113(5):647-56.
• [10]Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al.: Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013, 3(8):e003423.
• [11]Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26(3):917-32.
• [12]Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al.: Prevalence and control of diabetes in Chinese adults. JAMA 2013, 310(9):948-59.
• [13]van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990, 82(3):848-55.
• [14]Querton L, Buysschaert M, Hermans MP: Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol 2012, 6(5):434-42.
• [15]Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37(4):1053-9.
• [16]Hunt KJ, Gebregziabher M, Egede LE: Racial and ethnic differences in cardio-metabolic risk in individuals with undiagnosed diabetes: National Health and Nutrition Examination Survey 1999–2008. J Gen Intern Med 2012, 27(8):893-900.
• [17]Brown TM, Tanner RM, Carson AP, Yun H, Rosenson RS, Farkouh ME, et al.: Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care 2013, 36(9):2734-40.
• [18]Yang G, Hu J, Rao KQ, Ma J, Rao C, Lopez AD: Mortality registration and surveillance in China: History, current situation and challenges. Popul Health Metrics 2005, 3(1):3. BioMed Central Full Text
• [19]Bull FC, Maslin TS, Armstrong T: Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health 2009, 6(6):790-804.
• [20]American Diabetes Association: Diagnosis and classification of diabetes mellitus Diabetes Care 2010, 33 Suppl 1:S62-9.
• [21]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama 2003, 289(19):2560-72.
• [22]Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-39.
• [23]Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-47.
• [24]National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Circulation 2002, 106(25):3143-421.
• [25]Ford ES, Li C, Sniderman A: Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988–1991 to 2005–2008. Cardiovasc Diabetol 2013, 12:26. BioMed Central Full Text
• [26]Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al.: Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case–control study in 13 countries. Circulation 2014, 129(9):999-1008.
• [27]Wasem J, Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, et al.: Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy–an analysis of the DiaRegis registry. Cardiovasc Diabetol 2013, 12:47. BioMed Central Full Text
• [28]Taubert G, Winkelmann BR, Schleiffer T, Marz W, Winkler R, Gok R, et al.: Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003, 145(2):285-91.
• [29]Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D, Brogan GX Jr, et al.: Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J 2013, 165(6):918-25. e912
• [30]Lauruschkat AH, Arnrich B, Albert AA, Walter JA, Amann B, Rosendahl UP, et al.: Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation 2005, 112(16):2397-402.
• [31]Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W: Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2011, 34(1):34-8.
• [32]Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-91.
• [33]Nagao H, Kashine S, Nishizawa H, Okada T, Kimura T, Hirata A, et al.: Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovasc Diabetol 2013, 12:88. BioMed Central Full Text
• [34]Saydah S, Bullard KM, Cheng Y, Ali MK, Gregg EW, Geiss L, et al.: Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999–2010. Obesity (Silver Spring) 2014, 22:1888-95.
• [35]Kones R, Rumana U: Prevention of cardiovascular disease: updating the immensity of the challenge and the role of risk factors. Hosp Pract (1995) 2014, 42(1):92-100.